Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells.

Kelly-Anne MastermanOscar L HaighKirsteen M TullettIngrid M Leal-RojasCarina WalpoleFrances E PearsonJonathon CebonChristopher SchmidtLiam O'BrienNikita RosendahlGhazal DarajIrina CaminschiEric H GschwengRoger P HollisDonald B KohnMireille H LahoudKristen J Radford

Published in: Journal for immunotherapy of cancer (2021)

These data advocate human CLEC9A-NY-ESO-1 Ab as an attractive strategy for specific targeting of CD141+ DCs to enhance tumor immunogenicity in NY-ESO-1-expressing malignancies.

Keyphrases

dendritic cells
endothelial cells
induced pluripotent stem cells
pluripotent stem cells
immune response
working memory
cancer therapy
electronic health record
nk cells
big data
machine learning
drug delivery
artificial intelligence